The Long-Awaited Massachusetts Health Policy Commission Accountable Care Organization Certification Standards Are Here

December 15, 2015 Alerts and Newsletters

Under Chapter 224 of the Acts of 2012 ("Chapter 224"), the Massachusetts Health Policy Commission ("HPC"), which was created under that Act, is required to establish a process for the voluntary certification of accountable care organizations ("ACOs"). On December 9, 2015, the HPC released the long-awaited "Proposed Accountable Care Organization (ACO) Certification Standards" ("Proposed Standards") for public comment. These proposed certification standards address core competencies for ACOs in care delivery and are designed to ensure that certification is attainable for systems of differing sizes, infrastructure and technical capabilities, populations served, and locations.

Chapter 224 lists a number of mandatory minimum standards for the certification of ACOs and authorizes the HPC to develop additional standards that are consistent with the goals for ACO certification set forth in Chapter 224. Acting on this authority the HPC has proposed thirty one criteria for ACO certification (some of which have various documentation requirements), which are grouped in the following three categories:

  • General mandatory criteria, which address the legal and governance structure of the ACO, risk stratification and population specific interventions, the provision of care across the continuum, participation in MassHealth alternative payment methodologies, patient centered medical home adoption rates, cost, utilization, and quality analytics, patient and family experience, and community health;
  • Market and patient protection criteria, which address risk-bearing provider organization status, HPC material change notice compliance, compliance with federal and state antitrust laws, compliance with HPC's Office of Patient Protection guidance concerning patient grievances, quality and financial performance reporting, and consumer price transparency; and
  • Reporting only criteria, which require reporting in the areas of palliative care, care coordination, peer support, adherence to evidence-based guidelines, alternative payment methodology adoption for primary care, flow of payments to providers, ACO population demographics and preferences, and commitment to electronic health record interoperability.

Unlike the "general mandatory criteria" and the "market and patient protection criteria," the HPC will review the ACO's responses to the "reporting only criteria" but will not qualitatively assess these responses. Rather, the HPC will reference and rely on this reported information when making future changes or adjustments to the ACO certification program. Note that the Proposed Standards make no mention of the concept introduced in Chapter 224 under which certain ACOs designated as "model ACOs" could receive preferential contracting under state health programs.

The HPC is seeking stakeholders' comments and perspectives on the proposed ACO certification framework, criteria, and documentation requirements. In particular, the HPC asks specific questions concerning certain criteria and also poses eight general questions regarding the ACO certification framework. Comments on the Proposed Standards are due to the HPC by 5:00 pm on January 29, 2016. The HPC will also hold a public hearing on January 6, 2016 to discuss the Proposed Standards.

The Health Care Group at Verrill Dana is analyzing the criteria set forth in the Proposed Standards and considering the submission of comments. For more information, to suggest comments, or to request assistance in submitting your own comments, please contact any member of the Health Care Group at Verrill Dana.

___________________________________________________________________
This communication is intended for general information purposes and as a service to clients and friends of Verrill Dana, LLP. This publication, which may be considered advertising under the ethical rules of certain jurisdictions, should not be construed as legal advice or a legal opinion on any specific facts or circumstances, nor does it create attorney-client privilege.

Firm Highlights

Publication/Podcast

News Flash: HHS Issues Statement Removing Premarket Review Requirements for Laboratory Developed Tests (“LDTs”), Including COVID-19 LDTs

What happened? On August 19, 2020, the U.S. Department of Health and Human Services (“HHS”) issued a single paragraph statement rescinding U.S. Food and Drug Administration (“FDA”) guidance documents concerning premarket review of Laboratory...

Publication/Podcast

EU-U.S. Privacy Shield Invalidated: Does Your Company Have a Plan B?

On Thursday, July 16, 2020, the Court of Justice of the European Union (“CJEU”) invalidated the EU-U.S. Privacy Shield (“Privacy Shield”) in Data Protection Commissioner v. Facebook Ireland and Maximillian Schrems (Case C-311/18...

News

38 Verrill Attorneys, Across Four Offices, Recognized in 2020 Chambers & Partners Guide

(April 27, 2020) – Verrill has been rated as a Leading Firm in a total of ten categories and subcategories as evaluated by London-based Chambers & Partners , one of the world's most respected...

Publication/Podcast

FDA Updates its Guidance on Conducting Clinical Trials During COVID-19 Public Health Emergency

On April 16, 2020, the U.S. Food & Drug Administration (“FDA”) again updated its guidance on the “Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency,” adding seven new questions and...

Publication/Podcast

FDA Issues Guidance on IRB Review of Non-Emergency Individual Patient Expanded Access Requests for Investigational Drugs and Biological Products to Treat COVID-19

Prompted by a substantial increase in requests for individual patient access to investigational drugs and biologics to treat COVID-19, the U.S. Food & Drug Administration (“FDA”) issued guidance on June 2, 2020 that outlines...

News

Michael K. Fee to Lead Verrill’s Nationally-Recognized Health Care and Life Sciences Practice Amidst Recent Changes

(August 31, 2020) – Verrill is pleased to announce Michael K. Fee as the new leader of Verrill’s nationally-recognized Health Care & Life Sciences Group. The Group has a long history of representing a...

News

Nearly 80 Verrill Attorneys Recognized by Best Lawyers® 2021, Including a Dozen Named Lawyers of the Year

(August 24, 2020) – Nearly 80 Verrill attorneys were recognized as "Best Lawyers" by Best Lawyers® 2021 , including 12 attorneys named “Lawyer of the Year,” a distinguished recognition for only a single lawyer...

Matter

Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...

Matter

Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.

Matter

European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...